1. Market Research
  2. > Pharmaceutical Market Trends

Transition at Teva: Blockbuster drug Copaxone to lose patent protection in 2014

  • April 2014
  • 21 pages
  • MarketLine
Report ID: 2188849

Summary

Table of Contents

Search Inside

Introduction

In October 2013, Teva announced that it would be cutting approximately 10% of the workforce in order to cut costs. Later that month, it announced the departure of its CEO of just 18 months, Jeremy Levin, who was forced out by Chairman Phillip Frost. This case study looks out how Teva, one of the largest pharmaceuticals companies in the world, has ended up in this position, & what the future holds

Features and benefits

* This case study looks at Teva's operations and the market in which it operates. It also looks in detail at Copaxone, Teva's best-selling drug.
* The case study examines the M&A activity Teva has been involved in over recent years, and whether or not it has been successful.
* Teva's future engines of growth are discussed, as well as 2 outlooks for 2014, depending on generic competition for Copaxone.

Highlights

In the US, one in every seven prescriptions is filled with a Teva product, and in the UK, this rises to one in every six prescriptions. The company operates in over 60 countries worldwide and employs approximately 45,000 people. Teva has over 55,000 product variants and 1,000 molecules, and manufactured 64 billion tablets and capsules in 2013.
Copaxone is one of Teva's best-selling drugs, with global sales of $3.9bn in 2012 and $4.3bn in 2013. Copaxone accounted for 49% of the specialty drugs segment's sales in 2012, rising to 52% in 2013. However, Copaxone may face generic competition as early as May 2014.
The New Therapeutic Entities (NTE) program, launched in December 2012, uses existing, known molecules that can offer improvements for patients by being formulated, delivered or used in a novel way. Development of NTEs is less time consuming, less risky, and less expensive.

Your key questions answered

* Why is Copaxone losing patent protection and what is Teva doing to alleviate this?
* What is the NTE program?
* What is the outlook for Teva in 2014?

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 60 Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

Amrita helps you find the right report:

Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

Purchase Reports From Reputable Market Research Publishers

Clinical Chemistry Reagents and Analyzers Market 2021: A 74-Country Analysis--Supplier Shares and Strategies, Volume and Sales Segment Forecasts, Technology and Instrumentation Review

  • $ 75000
  • Industry report
  • May 2017
  • by Venture Planning Group

This new 74-country report from VPGMarketResearch.com is available by region, country, market segment, section, or individual test. Please contact Client Services at reports@vpgcorp.com or +1 212 564 ...

Immunodiagnostics Analyzers and Reagents Market 2021: A 74-Country Analysis--Supplier Shares and Strategies, Volume and Sales Segment Forecasts, Technology and Instrumentation Review

  • $ 75000
  • Industry report
  • July 2017
  • by Venture Planning Group

This new 74-country survey from VPGMarketResearch.com provides a granular strategic analysis of over 100 clinical chemistry, TDM, endocrine, cancer, immunoprotein and abused drug assays performed in both ...

Cancer Diagnostics Market 2021: A 74-Country Analysis--Supplier Shares and Strategies, Emerging Tumor Markers, Volume and Sales Segment Forecasts, Technology and Instrumentation Review

  • $ 52400
  • Industry report
  • May 2017
  • by Venture Planning Group

This new 74-country report from VPGMarketResearch.com is available by region, country, market segment, section, or individual test. This report is designed to assist diagnostics industry executives, as ...


ref:plp2014

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.